Tags: Drug.
Blisibimod (also known as A-623 formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF also known as B-lymphocyte stimulator or BLyS) being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials.